These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
341 related articles for article (PubMed ID: 17768067)
1. Immune-refractory cancers and their little helpers--an extended role for immunetolerogenic MHC molecules HLA-G and HLA-E? Wischhusen J; Waschbisch A; Wiendl H Semin Cancer Biol; 2007 Dec; 17(6):459-68. PubMed ID: 17768067 [TBL] [Abstract][Full Text] [Related]
2. Expression of the immune-tolerogenic major histocompatibility molecule HLA-G in multiple sclerosis: implications for CNS immunity. Wiendl H; Feger U; Mittelbronn M; Jack C; Schreiner B; Stadelmann C; Antel J; Brueck W; Meyermann R; Bar-Or A; Kieseier BC; Weller M Brain; 2005 Nov; 128(Pt 11):2689-704. PubMed ID: 16123145 [TBL] [Abstract][Full Text] [Related]
3. HLA-G in B-chronic lymphocytic leukaemia: clinical relevance and functional implications. Rebmann V; Nückel H; Dührsen U; Grosse-Wilde H Semin Cancer Biol; 2007 Dec; 17(6):430-5. PubMed ID: 17683947 [TBL] [Abstract][Full Text] [Related]
4. HLA-G and its KIR ligands in cancer--another enigma yet to be solved? Urosevic M; Trojan A; Dummer R J Pathol; 2002 Mar; 196(3):252-3. PubMed ID: 11857486 [TBL] [Abstract][Full Text] [Related]
5. Specific activation of the non-classical class I histocompatibility HLA-G antigen and expression of the ILT2 inhibitory receptor in human breast cancer. Lefebvre S; Antoine M; Uzan S; McMaster M; Dausset J; Carosella ED; Paul P J Pathol; 2002 Mar; 196(3):266-74. PubMed ID: 11857488 [TBL] [Abstract][Full Text] [Related]
6. Expression of tolerogenic HLA-G molecules in cancer prevents antitumor responses. Rouas-Freiss N; Moreau P; Menier C; LeMaoult J; Carosella ED Semin Cancer Biol; 2007 Dec; 17(6):413-21. PubMed ID: 17881247 [TBL] [Abstract][Full Text] [Related]
7. HLA-G expression in malignant melanoma. Rebmann V; Wagner S; Grosse-Wilde H Semin Cancer Biol; 2007 Dec; 17(6):422-9. PubMed ID: 17689098 [TBL] [Abstract][Full Text] [Related]
8. Non-classical HLA-G antigen and its role in the cancer progression. Tripathi P; Agrawal S Cancer Invest; 2006 Mar; 24(2):178-86. PubMed ID: 16537188 [TBL] [Abstract][Full Text] [Related]
9. HLA-G expression: immune privilege for tumour cells? Cabestre FA; Lefebvre S; Moreau P; Rouas-Friess N; Dausset J; Carosella ED; Paul P Semin Cancer Biol; 1999 Feb; 9(1):27-36. PubMed ID: 10092548 [TBL] [Abstract][Full Text] [Related]
10. Structure, expression and function of HLA-G in renal cell carcinoma. Seliger B; Schlaf G Semin Cancer Biol; 2007 Dec; 17(6):444-50. PubMed ID: 17707652 [TBL] [Abstract][Full Text] [Related]
11. Capacity of myeloid and plasmacytoid dendritic cells especially at mature stage to express and secrete HLA-G molecules. Le Friec G; Gros F; Sebti Y; Guilloux V; Pangault C; Fauchet R; Amiot L J Leukoc Biol; 2004 Dec; 76(6):1125-33. PubMed ID: 15331623 [TBL] [Abstract][Full Text] [Related]
12. HLA-G-dependent suppressor cells: Diverse by nature, function, and significance. Carosella ED; HoWangYin KY; Favier B; LeMaoult J Hum Immunol; 2008 Nov; 69(11):700-7. PubMed ID: 18817832 [TBL] [Abstract][Full Text] [Related]
13. The role of HLA-G in gastrointestinal inflammatory disease and malignancy. Downs-Kelly E; Schade AE; Hansel DE Semin Cancer Biol; 2007 Dec; 17(6):451-8. PubMed ID: 17716911 [TBL] [Abstract][Full Text] [Related]
14. HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism? Rouas-Freiss N; Moreau P; Ferrone S; Carosella ED Cancer Res; 2005 Nov; 65(22):10139-44. PubMed ID: 16287995 [TBL] [Abstract][Full Text] [Related]
15. Human leukocyte antigen-G in cancer: are they clinically relevant? Yan WH Cancer Lett; 2011 Dec; 311(2):123-30. PubMed ID: 21843913 [TBL] [Abstract][Full Text] [Related]
16. HLA-G1-expressing antigen-presenting cells induce immunosuppressive CD4+ T cells. LeMaoult J; Krawice-Radanne I; Dausset J; Carosella ED Proc Natl Acad Sci U S A; 2004 May; 101(18):7064-9. PubMed ID: 15103024 [TBL] [Abstract][Full Text] [Related]
17. [Importance of HLA-G in therapy of cancer]. Zidi I; Bartegi A Therapie; 2008; 63(4):327-32. PubMed ID: 18937912 [TBL] [Abstract][Full Text] [Related]
18. Subtle changes in peptide conformation profoundly affect recognition of the non-classical MHC class I molecule HLA-E by the CD94-NKG2 natural killer cell receptors. Hoare HL; Sullivan LC; Clements CS; Ely LK; Beddoe T; Henderson KN; Lin J; Reid HH; Brooks AG; Rossjohn J J Mol Biol; 2008 Apr; 377(5):1297-303. PubMed ID: 18339401 [TBL] [Abstract][Full Text] [Related]
19. The immunotolerance role of HLA-G. Rouas-Freiss N; Khalil-Daher I; Riteau B; Menier C; Paul P; Dausset J; Carosella ED Semin Cancer Biol; 1999 Feb; 9(1):3-12. PubMed ID: 10092545 [TBL] [Abstract][Full Text] [Related]
20. Tolerance versus immune response -- microRNAs as important elements in the regulation of the HLA-G gene expression. Veit TD; Chies JA Transpl Immunol; 2009 Mar; 20(4):229-31. PubMed ID: 19038339 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]